Trials / Completed
CompletedNCT01139346
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
Phase I Study of Oral Darinaparsin in Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Alaunos Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Phase I, dose escalation study of oral darinaparsin for the treatment of advanced solid tumors. Eligible patients could have received any amount of previous therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | darinaparsin | dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle. |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2010-06-08
- Last updated
- 2012-07-19
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01139346. Inclusion in this directory is not an endorsement.